3692 — Hansoh Pharmaceutical Share News
0.000.00%
Last trade - 00:00- HK$192.43bn
- HK$153.55bn
- CNY15.03bn
Brief: Hansoh Pharmaceutical Says NDA For Olatorepatide Injection Accepted By China's NMPA
J&T Global Express leads gain in newcomers to Hang Seng Index
Brief: Hansoh Pharmaceutical Says HS-10541 Tablets Obtain Clinical Trial Approval From China's NMPA
Brief: Hansoh Pharmaceutical Says NMPA Grants Breakthrough-Therapy Designation To Hansoh Pharma's HS-20093 For ESCC
Brief: Hansoh Pharmaceutical Transfers Kiomedinevsone License To Jiangsu Hengrui Pharmaceuticals
Brief: Hansoh Pharmaceutical Says NMPA Grants Breakthrough-Therapy Designation To Hs-20093 With Adebrelimab
GSK sees blockbuster potential in targeted cancer therapy after promising early data
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval
Hansoh jumps most in 19 months on annual profit beat, Citi lifts target price
China's Hansoh Pharmaceutical Group beats net profit expectations in 2025
Brief: Hansoh Pharmaceutical Says Xinyue (Inebilizumab Injection) Granted NMPA Approval For New Indication
Brief: Hansoh Pharmaceutical Says HS-20152 Injection Receives Clinical Trial Approval From NMPA
Brief: Hansoh Pharmaceutical Gets Clinical Trial Approval For HS-10587 Tablets Issued By NMPA China
Regeneron rises after announcing positive trial data on weight-loss drug
Factbox: Top pharma companies racing to launch a weight-loss pill
Brief: Hansoh Pharmaceutical Says New Drug Application Of Dalmelitinib Mesylate Tablets Accepted By NMPA
Brief: Hansoh Pharmaceutical Says Aumolertinib Mesylate Tablets Approved In EU As Monotherapy